Racura Oncology has enrolled the first patient in its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib to tackle resistance in EGFR-mutant non-small cell lung cancer. This milestone sets the stage for a multi-centre study aiming to improve treatment outcomes.
- First patient recruited at Monash Health for HARNESS-1 Phase 1 trial
- Trial tests RC220 combined with osimertinib in EGFR-mutant NSCLC patients
- Dose escalation to identify maximum tolerated dose using Bayesian design
- Multi-centre trial with additional sites to open soon
- Focus on overcoming resistance to current standard-of-care therapies
A Significant Step in Lung Cancer Research
Racura Oncology has announced a key milestone in its clinical development program with the recruitment of the first patient into the HARNESS-1 Phase 1 trial. This study evaluates the safety and pharmacokinetics of RC220, a novel anticancer agent, in combination with the widely used tyrosine kinase inhibitor osimertinib, targeting patients with EGFR-mutant non-small cell lung cancer (NSCLC).
Monash Health in Clayton, Victoria, led the initial patient enrolment under the guidance of Associate Professor Surein Arulananda. The trial aims to address a pressing clinical challenge: resistance to osimertinib, which remains a major hurdle in treating this aggressive lung cancer subtype.
Innovative Trial Design and Objectives
The HARNESS-1 trial employs a sophisticated approach, starting with circulating tumour DNA screening to identify eligible patients. It then proceeds through a dose escalation phase using a Bayesian Optimal Interval design, allowing researchers to efficiently determine the maximum tolerated dose of RC220 when combined with osimertinib.
This adaptive methodology balances patient safety with the need to rapidly identify effective dosing, aligning with the US FDA’s Project Optimus initiative aimed at optimising cancer drug dosing strategies. Following dose escalation, the trial will expand into a randomized, double-blind Phase 1b stage to further evaluate safety and preliminary efficacy.
Broader Implications and Next Steps
Racura’s CEO, Dr Daniel Tillett, emphasised the importance of this milestone, thanking the clinical teams and patients involved. The company plans to activate four additional clinical sites in the coming months, signalling a robust recruitment effort ahead.
Beyond lung cancer, Racura is advancing RC220 across multiple oncology indications, including acute myeloid leukaemia and solid tumours, leveraging its unique mechanism of targeting cancer growth regulators. The ongoing development of RC220, backed by new patent protections, positions Racura as a notable player in the oncology biotech sector.
While early in its clinical journey, the HARNESS-1 trial’s progress will be closely watched by investors and clinicians alike, as it holds promise for improving outcomes in a patient population with limited options once resistance to current therapies develops.
Bottom Line?
As Racura expands its trial network and advances dosing studies, the oncology community awaits data that could reshape treatment for resistant lung cancer.
Questions in the middle?
- How quickly will additional clinical sites begin enrolling patients?
- What early safety signals will emerge from the dose escalation phase?
- Could RC220’s mechanism translate into broader applications beyond EGFR-mutant NSCLC?